US2951011A - Silicone composition for the relief of gastro-intestinal distress and method of using same - Google Patents
Silicone composition for the relief of gastro-intestinal distress and method of using same Download PDFInfo
- Publication number
- US2951011A US2951011A US628576A US62857656A US2951011A US 2951011 A US2951011 A US 2951011A US 628576 A US628576 A US 628576A US 62857656 A US62857656 A US 62857656A US 2951011 A US2951011 A US 2951011A
- Authority
- US
- United States
- Prior art keywords
- organopolysiloxane
- gastro
- particles
- relief
- intestinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/04—Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
Definitions
- One of the. objects of this invention is to provide aparticulate therapeutic composition, the individual particles of which carry. a wall protecting material.
- Another object is to provide such a composition in which theprotective coating material serves to relieve flatulence. 7
- a therapeutic composition is provided in dry, particulate form, the individual particles of which are coated with one of'the;v organo-silicon oxide polymers (or organopolysiloxanes), more popularly known as silicones.
- the organopolysiloxanes are generally insoluble,.jellylike or-fluent. substances, not miscible with body fluids. Their administration, plain, deposits in the stomachi a relatively compact mass in a small area, whence it is passed through the intestinal tract, substantially without dispersion, and substantially without effect. They have been suggested as enteric coatings, and as such may be more thoroughly dispersed in the. intestinal'tract. However, their use as enteric coatings has not been satisfactory (fDrug- Standards, vol. 24, No. 1, pp.
- organopolysiloxane which can be carried on the surface of a tablet, relative to the volume of 7 material inv the tablet, without completely preventing, disintegrationof the tablet, is so small as to give-noefiec- 'tive protection to the walls of the gastro-intestinaltract, and to exert no appreciable anti-flatulent efliect.
- the supporting particles upon internal administration of the mixture, the supporting particles will be widely dispersed against the walls of the alimentary tract, carrying with them the supported organopolysilox-ane.
- the supporting-substance-1 is. of' suchcharacterthat it is dissolved, disintegrated or decomposed within the gastro-intestinal tract, or any selected portion thereof, the organopolysiloxane particles, being chemically and mechanically unaffected within the tract, will be deposited, in such widely dispersed condition, upon the .walls of the tract.
- the word disintegrated is used to encompass dissolution and decomposition.
- the Walls'of that tract (or of such selected portion or portions thereof) will be provided with a coating which not only'provides the mechanically protectiveeffect above-mentioned, but also will introduce, at those locations; a defoaming action; Even if the supporting substance isnot so: attacked, at least some of the supported organopolysiloxane will be deposited, in wide dispersion, upon the tract walls.
- organopolysiloxanes may elfectively be supported in the manner above-described upon many non-toxic substances.
- gastric antacids including aluminum hydroxide, magnesium carbonate, magnesium trisilicate, sodium bicarbonate, calcium caseinate, magnesium. oxide, calcium. carbonate, sodium carboxymethylcellulose, aluminum aminoacet-ate, calcium phosphate,. aluminum".
- any of these substances may be effectively used as carriers-for the organopolysiloxanes in the preparation of a composition according to the present invention.
- Thesolidcarrier in Bennettly-divided state, is intimately mixed, in accordance with conventional pharmaceutical practice, with-the selected organopolysiloxane, to the end that each particle of the carrier shall be, in effect, coated with theorganopolysiloxane.
- the. proportions ofthe. ingredients will preferably, that theultimate mixture remains discrete and fluent, and of granularcharacter suitable for direct administration or for compression totablet-form. Such a mixture may then be compressed. into tablet form, with or Without therapeutically inert filler materials such as cane sugar, milk sugar, starch, talc, or the like, and with or without suitable, non-toxic, binder substances.
- organopolysiloxane is between 5% and 50% of theweightof the dry particulate material.
- organopol-ysiloxane siinilarlyc'anid upon other types, of carriers, includingicarrierswhicli'have no therapeutic eliect.
- a selected organopolysiloxane might be intimately mixed with talc, starch or the like alone, and then compressed into ltablet dosage form or dispersed in a suitable liquid vehicle.v .
- The-protectivecoafi ing effect and the anti-flatulence eifectcan thereby beattained; other medication, concurrently, is not required.
- one of the organopolysiloxanes may similarly be administered in intimate mixture with an anion exchange resin such-as, for'instance, polyethylenepolyaminemethylene substituted resin' of diphenylol dimethylmethane and formaldehyde in basic form, to provide an antacid effect along with the coating and anti-foaming effects.
- an anion exchange resin such-as, for'instance, polyethylenepolyaminemethylene substituted resin' of diphenylol dimethylmethane and formaldehyde in basic form
- organopolysiloxane forms of intestinal medication other than antacid substances, such, for instance, as atropine or its substantial therapeutic equivalents, nonabsorbable sulfonamides, adsorbents, and so forth.
- a selected one of the iorganopolysiloxanes may be, to that end, analogously intimately mixed with the selected medicament for administration in the manner above outlined.
- my invention contemplates the administration of an organopolysiloxane dispersed with any non-toxic solid which is capable of mechanically supporting the organopolysiloxane in widely-dispersed condition, and which is capable of transferring at least some of the supported organopolysiloxane 'to the walls of the alimentary tract (or. someselected portion thereof) through mechanical action or through being digested, dissolved, disintegrated or decomposed in the presence of fluids to be found in the alimentary tract.
- compositions may be prepared in widely varying proportions and may be extended with any desired excipient, including the sugars, water, starch, flavoring agents, coloring agents, preserva tives, talc, stearates, and the like.
- organopolysiloxanes preferably selected for use in the composition are represented by the following formulae:
- R is a cH or other organic radical and 21:0 to 2000.
- ingredients and th proportions thereof, in antacid-organopolysiloxane compositions are given below; but it is to be understood that these are intended to be illustrative and not limitative:
- Example 5 Dihydroxy aluminum aminoacetate gm 0.5 Methyl polysiloxane L mg 10-25
- Example 6 Magnesium trisilicate gm 0.5 Aluminum hydroxide gel gm 0.25 Methyl polysiloxane mg 10-25
- Example 7 Bismuth subcarbonate gm 0.5 Calcium phosphate, tribasic gm 0.5 Kaolin gm 2.0 Pectin gm 0.26 Phthalylsulfacetamide gm 1.0 Belladonna, tincture cc 0.6 Dimethyl polysiloxane mg 50-200
- Example 8 Sodium bicarbonate gm 0.275 Calcium carbonate gm 0.15 Magnesium carbonate gm... 0.1
- a therapeutic composition comprising particulate, granular, disintegrable antacid material, the particles-of which are coated with a non-toxic organopolysiloxane, said organopolysiloxane being present in an amount between 1% and 10% of the weight of the dry granular material, said composition containing 10 to 200 milligrams of said organopolysiloxane per dosage unit, being sufiicient to coat said particles and to exert a wall protective and anti-flatulent effect upon the gastro-intestinalsystem but to leave said particles discrete and fluent.
- a method of treating gastro-intestinal distress which consists of administering orally to a human patient-a.
- composition comprising a particulate carriercoatedwith a non-toxic organopolysiloxane, said organopolysiloxane being present in the amount of 1% to 50% by weight of said carrier, said composition containing 10 to 200 milligrams of said organopolysiloxane per dosage unit.
Description
HE aw United States Patent SIEICONE COMPOSITION FOR THE RELIEF OF GASTRO-INTESTINAL DISTRESS AND METHOD OF USING SAME Wolife Harry Feinstone, Indianapolis, Ind. (121 Yates Road, Memphis 17, Ten.)
N Drawing.- Filed Dec. '17-, 1956, Ser. No. 628,576
3 Claims. (Cl. '167--5.5)'
This application is a continuation-in-part of applicalion. Serial No. 395,847, filed December 2, 1953-, now abandoned This invention relates to a therapeutic compositionfor oral administration, and more particularly-to a composition" whereby the walls of the alimentary tract are protested against irritation and erosion.
One of the. objects of this invention is to provide aparticulate therapeutic composition, the individual particles of which carry. a wall protecting material.
Another object is to provide such a composition in which theprotective coating material serves to relieve flatulence. 7
Still other'objects will become apparent tothose skilled in;the"art'in the light of the following description.
In accordance with this invention, generally stated, a therapeutic composition is provided in dry, particulate form, the individual particles of which are coated with one of'the;v organo-silicon oxide polymers (or organopolysiloxanes), more popularly known as silicones.
The organopolysiloxanes are generally insoluble,.jellylike or-fluent. substances, not miscible with body fluids. Their administration, plain, deposits in the stomachi a relatively compact mass in a small area, whence it is passed through the intestinal tract, substantially without dispersion, and substantially without effect. They have been suggested as enteric coatings, and as such may be more thoroughly dispersed in the. intestinal'tract. However, their use as enteric coatings has not been satisfactory (fDrug- Standards, vol. 24, No. 1, pp. 1-9-2l), and the amount of organopolysiloxane which can be carried on the surface of a tablet, relative to the volume of 7 material inv the tablet, without completely preventing, disintegrationof the tablet, is so small as to give-noefiec- 'tive protection to the walls of the gastro-intestinaltract, and to exert no appreciable anti-flatulent efliect.
I have discovered that, if an organopolysiloxane is in- 'and supported by the individual particles of the carrier,
then; upon internal administration of the mixture, the supporting particles will be widely dispersed against the walls of the alimentary tract, carrying with them the supported organopolysilox-ane. Now, if the supporting-substance-1 is. of' suchcharacterthat it is dissolved, disintegrated or decomposed within the gastro-intestinal tract, or any selected portion thereof, the organopolysiloxane particles, being chemically and mechanically unaffected within the tract, will be deposited, in such widely dispersed condition, upon the .walls of the tract. In the appended claims, the word disintegrated is used to encompass dissolution and decomposition. It will be observed that When the silicone-coated particles stick to the surface of the gastrointestinal wall, the wall is protected at the precise point at which the erosive or irritant effect of the medicament is likely to be greatest, since the concentration of the solution formed when the particle is dissolved is greatest at the immediate locus of the par- 2,951,01 1 Patented Aug; 30,, 1960 intestinal tract in which the material disintegra'tes; As
a consequence, and in. part because of the recognizedacapacityof the organopolysiloxanes to resist attack by. substances present in the gastro-intestinal tract, the Walls'of that tract (or of such selected portion or portions thereof) will be provided with a coating which not only'provides the mechanically protectiveeffect above-mentioned, butalso will introduce, at those locations; a defoaming action; Even if the supporting substance isnot so: attacked, at least some of the supported organopolysiloxane will be deposited, in wide dispersion, upon the tract walls.
I have found that the organopolysiloxanes may elfectively be supported in the manner above-described upon many non-toxic substances. For the alleviation-of'hyperacidity, or even of the discomfort resulting from the normal acid condition ofgastro-intestinal fluids in the presence of an ulcerous condition, it is conventional to administer substances known as gastric antacids, including aluminum hydroxide, magnesium carbonate, magnesium trisilicate, sodium bicarbonate, calcium caseinate, magnesium. oxide, calcium. carbonate, sodium carboxymethylcellulose, aluminum aminoacet-ate, calcium phosphate,. aluminum". tn'silicate, magnesium phosphate, bismuth subcarbonate, aluminum phosphate, dihydroxy aluminum aminoacetate and potassium phosphate. Any of these substances" may be effectively used as carriers-for the organopolysiloxanes in the preparation of a composition according to the present invention. Thesolidcarrier, in afinely-divided state, is intimately mixed, in accordance with conventional pharmaceutical practice, with-the selected organopolysiloxane, to the end that each particle of the carrier shall be, in effect, coated with theorganopolysiloxane. Preferably, the. proportions ofthe. ingredientswill besuch. that theultimate mixture remains discrete and fluent, and of granularcharacter suitable for direct administration or for compression totablet-form. Such a mixture may then be compressed. into tablet form, with or Without therapeutically inert filler materials such as cane sugar, milk sugar, starch, talc, or the like, and with or without suitable, non-toxic, binder substances.
The preferred range of organopolysiloxane isbetween 5% and 50% of theweightof the dry particulate material. J
As will be apparent fromthe above discussion, desirable and beneficial resultscan be attained from the administration of an organopol-ysiloxane. siinilarlyc'anid upon other types, of carriers, includingicarrierswhicli'have no therapeutic eliect. Thus, a selected =organopolysiloxane might be intimately mixed with talc, starch or the like alone, and then compressed into ltablet dosage form or dispersed in a suitable liquid vehicle.v .The-protectivecoafi ing effect and the anti-flatulence eifectcan thereby beattained; other medication, concurrently, is not required.
I have found, further; that one of the organopolysiloxanes may similarly be administered in intimate mixture with an anion exchange resin such-as, for'instance, polyethylenepolyaminemethylene substituted resin' of diphenylol dimethylmethane and formaldehyde in basic form, to provide an antacid effect along with the coating and anti-foaming effects.
It may, on occasion, be desirable to employ, along with the organopolysiloxane, forms of intestinal medication other than antacid substances, such, for instance, as atropine or its substantial therapeutic equivalents, nonabsorbable sulfonamides, adsorbents, and so forth. A selected one of the iorganopolysiloxanes may be, to that end, analogously intimately mixed with the selected medicament for administration in the manner above outlined. Broadly stated, it may be said that my invention contemplates the administration of an organopolysiloxane dispersed with any non-toxic solid which is capable of mechanically supporting the organopolysiloxane in widely-dispersed condition, and which is capable of transferring at least some of the supported organopolysiloxane 'to the walls of the alimentary tract (or. someselected portion thereof) through mechanical action or through being digested, dissolved, disintegrated or decomposed in the presence of fluids to be found in the alimentary tract.
Of course, the compositions, as above-described, may be prepared in widely varying proportions and may be extended with any desired excipient, including the sugars, water, starch, flavoring agents, coloring agents, preserva tives, talc, stearates, and the like.
The organopolysiloxanes preferably selected for use in the composition are represented by the following formulae:
' [R SiO 2] n where x is a small whole number; 11:1 to 2000; and R is an organic radical; or
i i [-sr-oIi-sr-n a is where R is a cH or other organic radical and 21:0 to 2000.
In general, the essential ingredients of the composition of my invention will be combined in proportions within the broad range as follows, though in certain specific instances, the proportions may vary still further:
Antacid gm 0.l-l'.0 organopolysiloxane ..mg -100 That is to say, as is indicated in the specific examples hereafter set out, the optimum range of proportions of organopolysiloxane to antacid by weight, is between 1% and 10% of organopolysiloxane.
Some specific examples of the ingredients and th proportions thereof, in antacid-organopolysiloxane compositions, are given below; but it is to be understood that these are intended to be illustrative and not limitative:
4 Example 5 Dihydroxy aluminum aminoacetate gm 0.5 Methyl polysiloxane L mg 10-25 Example 6 Magnesium trisilicate gm 0.5 Aluminum hydroxide gel gm 0.25 Methyl polysiloxane mg 10-25 Example 7 Bismuth subcarbonate gm 0.5 Calcium phosphate, tribasic gm 0.5 Kaolin gm 2.0 Pectin gm 0.26 Phthalylsulfacetamide gm 1.0 Belladonna, tincture cc 0.6 Dimethyl polysiloxane mg 50-200 Example 8 Sodium bicarbonate gm 0.275 Calcium carbonate gm 0.15 Magnesium carbonate gm... 0.1 Magnesium trisilicate gm 0.07 Bismuth subcarbonate gm 0.002 Methyl polysiloxane mg 10-25 Having thus described my invention, what is claimed and desired to be secured by Letters Patent is:
- 1. A therapeutic composition comprising particulate, granular, disintegrable antacid material, the particles-of which are coated with a non-toxic organopolysiloxane, said organopolysiloxane being present in an amount between 1% and 10% of the weight of the dry granular material, said composition containing 10 to 200 milligrams of said organopolysiloxane per dosage unit, being sufiicient to coat said particles and to exert a wall protective and anti-flatulent effect upon the gastro-intestinalsystem but to leave said particles discrete and fluent.
V 2. A method of treating gastro-intestinal distress, which consists of administering orally to a human patient-a. composition comprising a particulate carriercoatedwith a non-toxic organopolysiloxane, said organopolysiloxane being present in the amount of 1% to 50% by weight of said carrier, said composition containing 10 to 200 milligrams of said organopolysiloxane per dosage unit.
, 3. The method of claim 2 wherein the composition is administered in tablet form.
. References Cited in the file of this patent UNITED STATES PATENTS 2,394,107 Roseman FebLjs, 1945 2,474,704 Thayer June 28, 1949 2,512,192 Yen June 20, 1950 OTHER REFERENCES
Claims (1)
1. A THERAPEUTIC COMPISITION COMPRISING PARTICULATE, GRANULAR, DISINTEGRAVLE ANTACID MATERIAL, THE PARTICLES OF WHICH ARE COATED WITH A NON-TOXIC ORGANOPOLYSILOXANE SAID ORGANOPOLYSILOXANE BEING PRESENT IN AN AMOUNT BETWEEN 1% AND 10% OF THE WEIGHT OF THE DRY GRANULAR MATERIAL, SAID COMPOSITION CONTAINING 10 TO 200 MILLIGRAMS OF SAID ORGANOPOLYSILOXANE PER DOSAGE UNIT, BEING SUFFICIENT TO COAT SAID PARTICLES AND TO EXERT A WALL PROTECTIVE AND ANTI-FLATULENT EFFECT UPON THE GASTRO-INTESTINAL SYSTEM BUT TO LEAVE SAID PARTICLES AND FLUENT.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US628576A US2951011A (en) | 1956-12-17 | 1956-12-17 | Silicone composition for the relief of gastro-intestinal distress and method of using same |
| BE601957A BE601957Q (en) | 1956-12-17 | 1961-03-29 | Therapeutic compound for alleviating gastrointestinal complaints and method of use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US628576A US2951011A (en) | 1956-12-17 | 1956-12-17 | Silicone composition for the relief of gastro-intestinal distress and method of using same |
| GB34676/60A GB914925A (en) | 1960-10-10 | 1960-10-10 | Therapeutic compositions containing organopolysiloxanes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2951011A true US2951011A (en) | 1960-08-30 |
Family
ID=26262393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US628576A Expired - Lifetime US2951011A (en) | 1956-12-17 | 1956-12-17 | Silicone composition for the relief of gastro-intestinal distress and method of using same |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2951011A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3094464A (en) * | 1960-04-01 | 1963-06-18 | Rech S Et Propagande Scient | Aspirin-antacid polysiloxane tablet |
| US3239414A (en) * | 1962-12-26 | 1966-03-08 | Robert L Rowan | Method for coating bladder and urethral mucosal surface |
| US3275509A (en) * | 1963-04-24 | 1966-09-27 | Robert L Rowan | Method for treating intestinal disorders with a silicone composition enema |
| US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
| US3422189A (en) * | 1959-01-02 | 1969-01-14 | Moraine Products | Method and compositions for the treatment of gastro-intestinal disorders |
| US4268496A (en) * | 1975-04-12 | 1981-05-19 | Shin-Etsu Chemical Co. Ltd. | Sustained-release solid pharmaceutical dosage forms and preparation thereof |
| US4396604A (en) * | 1982-05-17 | 1983-08-02 | Norcliff Thayer, Inc. | Simethicone antacid lozenge |
| WO1990007930A1 (en) * | 1989-01-19 | 1990-07-26 | Steigerwald Arzneimittelwerk Gmbh | Use of dimethylpolysiloxane for treating disorders of the gastrointestinal tract |
| EP0428296A2 (en) * | 1989-11-01 | 1991-05-22 | McNEIL-PPC, INC. | Pharmaceutical compositions for treating gastrointestinal distress |
| WO1992021325A1 (en) * | 1991-06-07 | 1992-12-10 | Union Metropolitaine Pharmaceutique | Oral composition based on an antibiotic material and clay |
| WO1993010797A1 (en) * | 1991-12-05 | 1993-06-10 | Paul Bolder Arzneimittelfabrik Gmbh & Co. Kg | Dimeticon pastilles |
| US20040063664A1 (en) * | 2002-09-30 | 2004-04-01 | Danielson Douglas W. | Simethicone containing tablet composition and method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2394107A (en) * | 1940-03-21 | 1946-02-05 | Charles H Burton | Gastro-intestinal magnesium silicate medicament |
| US2474704A (en) * | 1948-06-29 | 1949-06-28 | Dow Corning | Method of rendering materials water-repellent |
| US2512192A (en) * | 1948-05-26 | 1950-06-20 | American Cyanamid Co | Silicone resin medicament coating |
-
1956
- 1956-12-17 US US628576A patent/US2951011A/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2394107A (en) * | 1940-03-21 | 1946-02-05 | Charles H Burton | Gastro-intestinal magnesium silicate medicament |
| US2512192A (en) * | 1948-05-26 | 1950-06-20 | American Cyanamid Co | Silicone resin medicament coating |
| US2474704A (en) * | 1948-06-29 | 1949-06-28 | Dow Corning | Method of rendering materials water-repellent |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3422189A (en) * | 1959-01-02 | 1969-01-14 | Moraine Products | Method and compositions for the treatment of gastro-intestinal disorders |
| US3094464A (en) * | 1960-04-01 | 1963-06-18 | Rech S Et Propagande Scient | Aspirin-antacid polysiloxane tablet |
| US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
| US3239414A (en) * | 1962-12-26 | 1966-03-08 | Robert L Rowan | Method for coating bladder and urethral mucosal surface |
| US3275509A (en) * | 1963-04-24 | 1966-09-27 | Robert L Rowan | Method for treating intestinal disorders with a silicone composition enema |
| US4268496A (en) * | 1975-04-12 | 1981-05-19 | Shin-Etsu Chemical Co. Ltd. | Sustained-release solid pharmaceutical dosage forms and preparation thereof |
| US4396604A (en) * | 1982-05-17 | 1983-08-02 | Norcliff Thayer, Inc. | Simethicone antacid lozenge |
| US5120533A (en) * | 1989-01-19 | 1992-06-09 | Steigerwald Arzneimittelwerk Gmbh | Treatment of ulcers of the gastrointestinal tract using dimethylpolysiloxane |
| WO1990007930A1 (en) * | 1989-01-19 | 1990-07-26 | Steigerwald Arzneimittelwerk Gmbh | Use of dimethylpolysiloxane for treating disorders of the gastrointestinal tract |
| US5424064A (en) * | 1989-01-19 | 1995-06-13 | Schmidt; Alfred | Treatment of reflux esophagitis using dimethylpolysiloxane |
| US5277902A (en) * | 1989-01-19 | 1994-01-11 | Alfred Schmidt | Treatment of gastritis using dimethylpolysiloxane |
| GR900100785A (en) * | 1989-11-01 | 1992-04-17 | Mcneil Ppc Inc | A process for providing a composition comprising an antidiarrheal and an antiflatulent |
| AU634833B2 (en) * | 1989-11-01 | 1993-03-04 | Mcneil-Ppc, Inc. | Pharmaceutical compositions for treating gastrointestinal distress |
| US5248505A (en) * | 1989-11-01 | 1993-09-28 | Mcneil-Ppc, Inc. | Method for treating gastrointestinal distress |
| EP0428296A3 (en) * | 1989-11-01 | 1991-07-03 | Mcneil-Ppc, Inc. | Pharmaceutical compositions for treating gastrointestinal distress |
| EP0428296A2 (en) * | 1989-11-01 | 1991-05-22 | McNEIL-PPC, INC. | Pharmaceutical compositions for treating gastrointestinal distress |
| US5612054A (en) * | 1989-11-01 | 1997-03-18 | Mcneil-Ppc, Inc. | Pharmaceutical compositions for treating gastrointestinal distress |
| WO1992021325A1 (en) * | 1991-06-07 | 1992-12-10 | Union Metropolitaine Pharmaceutique | Oral composition based on an antibiotic material and clay |
| FR2677253A1 (en) * | 1991-06-07 | 1992-12-11 | Union Metropolitaine Pharmaceu | THERAPEUTIC COMPOSITION USEFUL FOR INFLAMMATORY DISEASES OF THE GASTROINTESTINAL SYSTEM. |
| WO1993010797A1 (en) * | 1991-12-05 | 1993-06-10 | Paul Bolder Arzneimittelfabrik Gmbh & Co. Kg | Dimeticon pastilles |
| US5633005A (en) * | 1991-12-05 | 1997-05-27 | Bolder Arzneimittel Gmbh | Dimeticon pastilles |
| US20040063664A1 (en) * | 2002-09-30 | 2004-04-01 | Danielson Douglas W. | Simethicone containing tablet composition and method |
| US7341742B2 (en) | 2002-09-30 | 2008-03-11 | L. Perrigo Company | Simethicone containing tablet composition and method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1173218B1 (en) | Mucosally adhesive compositions for the treatment of disorders of the oesophagus and their use. | |
| US4885281A (en) | Sucralfate suspension | |
| US2951011A (en) | Silicone composition for the relief of gastro-intestinal distress and method of using same | |
| US3843778A (en) | Antacids | |
| KR100780156B1 (en) | Taste masking coating composition | |
| ES2370729T3 (en) | INFLATABLE PHARMACEUTICAL FORM INCLUDING GELLAN RUBBER. | |
| EP0011489B1 (en) | An analgesic effervescent powder and process for its preparation | |
| JPH03151005A (en) | Mixture of maltdextrin and defoaming composition | |
| WO1990007344A1 (en) | Liquid sustained release composition | |
| US4764374A (en) | Pharmaceutical composition based on guar gum and other antacids for protection of the oesogastroduodenal mucous membrane | |
| JPH11504911A (en) | Composition containing amoxicillin and clavulanic acid | |
| USRE25205E (en) | Silicone composition for the relief of | |
| US4704278A (en) | Fluidized magaldrate suspension | |
| US3326754A (en) | Method of relieving gastrointestinal distress with tributyl phosphate | |
| WO1999056738A1 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| US5661137A (en) | Antacid pharmaceutical composition in the form of a suspension based on sucralfate gel | |
| Necheles et al. | Peptic Ulcer in Man Part 4. A New Antacid Made To Meet Requirements Of Antacid Therapy, Chemical And Laboratory Work | |
| NZ198858A (en) | Pharmaceutical composition containing sodium cromoglycate | |
| JPS5942318A (en) | Therapeutical composition, manufacture and use | |
| GB2105988A (en) | Anti-platelet aggregation dipyridamole with Al aspirin | |
| MXPA01011235A (en) | Compositions for treatment of disorders of the oesophagus | |
| JPS61263920A (en) | Medicinal composition | |
| JPS61109724A (en) | Encapsuled antacid dispersion |